Abbott (Abbott India)

What Abbott (Abbott India) does

Abbott India is the Indian operation of Abbott Laboratories, a global healthcare company headquartered in the United States and present in India since 1910. Abbott India employs 12,000+ people across the country and operates six manufacturing facilities (Chembur, Delhi, Baddi, Goa, Mumbai, Jhagadia). Its business spans four segments: diagnostics, medical devices, nutritionals, and branded generic medicines. The publicly listed Abbott India Ltd is the primary corporate entity, while additional operations sit within private Abbott India structures.

The company's technology portfolio is anchored by proprietary, minimally invasive medical devices with strong regulatory moats. Key products include the AVEIR VR and AVEIR DR leadless pacemakers (the latter being the world's first dual-chamber leadless pacemaker), the MitraClip transcatheter mitral valve repair system, the smartphone-compatible Insertable Cardiac Monitor (ICM) with Bluetooth connectivity, the FreeStyle Libre 2 Plus continuous glucose monitoring system, the Full MagLev Flow Technology LVAD, and pea-sized PDA closure devices for premature infants as small as 700 grams. Recent additions include the Navitor Vision heart valve, TactiFlex ablation catheter, PCV-14 pneumococcal vaccine, and a lab-based blood test for concussion evaluation. The portfolio is supported by landmark clinical evidence including the COAPT Trial published in the New England Journal of Medicine.

Abbott India monetizes through direct enterprise sales to hospitals and healthcare institutions for medical devices, distribution partnerships for pharmaceuticals (MSD for oral anti-diabetics, Novo Nordisk for semaglutide), and retail/wholesale channels for nutritionals and generics. GTM combines enterprise field sales targeting cardiologists and tertiary hospitals (Apollo, Max, Medanta, Fortis) with direct-to-consumer awareness campaigns such as 'Chakkar Ko Check Kar' for vertigo. The a:care Congress platform, endorsed by 60+ medical societies and engaging 75,000 HCPs (50,000 from India), anchors physician engagement around medication adherence. Named reference customers for advanced cardiac devices are concentrated among India's premium hospital chains, while the consumer health and generics businesses provide broader distribution reach across urban and rural India.

Name

Abbott (Abbott India)

Legal name

Abbott India Ltd

Website

https://abbott.in

Company type

Private

Founded year

1888

Operating status

Operating

Short description

Abbott India is the Indian subsidiary of global healthcare company Abbott Laboratories, operating since 1910 with 12,000+ employees across diagnostics, medical devices, nutritionals, and branded generic medicines. It sells proprietary cardiac, diabetes, and structural heart products to hospitals, physicians, and consumers across India.

Ownership category

akta.pro rank

Product category

Medical Devices and Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Medical devices
• Diagnostics
• Cardiac rhythm management
• Continuous glucose monitoring
• Branded generic pharmaceuticals

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Diagnostics: Abbott operates leading diagnostics business providing laboratory diagnostics, point-of-care testing, and molecular diagnostics solutions to healthcare providers.
2. Medical Devices: Portfolio including cardiac rhythm management, structural heart, diabetes care (FreeStyle Libre), vascular devices, and neuromodulation products sold to hospitals and healthcare professionals.
3. Nutritionals: Nutrition products including pediatric nutrition, adult nutrition, and sports nutrition supplements sold through retail and healthcare channels.
4. Branded Generic Medicines: Pharmaceutical products including established brands across multiple therapeutic areas including diabetes, cardiovascular, women's health, and other chronic conditions.
5. a:care Congress Educational Initiative: Global educational initiative on medication adherence endorsed by more than 60 national and international medical societies, focusing on behavioral science and digital solutions.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Abbott India manufactures and sells a diversified healthcare portfolio across diagnostics, medical devices, nutritionals, and branded generic medicines. Medical devices include continuous glucose monitoring (FreeStyle Libre 2 Plus), leadless pacemakers (AVEIR VR and AVEIR DR), transcatheter mitral valve repair (MitraClip), insertable cardiac monitors, ablation catheters, structural heart valves, pediatric cardiac devices, and left ventricular assist devices. The company also provides nutritional supplements, oral anti-diabetic pharmaceuticals distributed in partnership with MSD and Novo Nordisk, and digital health initiatives including the a:care medication adherence platform.

Product overview

Abbott India operates as a diversified healthcare company with a broad portfolio spanning four major business areas: diagnostics, medical devices, nutritionals, and branded generic medicines. The medical devices segment includes cardiovascular products (leadless pacemakers AVEIR VR/DR, MitraClip for mitral valve repair, Insertable Cardiac Monitor, TactiFlex ablation catheter, Navitor Vision heart valve), diabetes care (FreeStyle Libre 2 Plus continuous glucose monitoring system), and pediatric cardiac devices (PDA closure device for premature babies). Abbott also offers digital health initiatives including the a:care platform for medication adherence, maintains disease surveillance through the Abbott Pandemic Defense Coalition, and provides diagnostic imaging solutions like OCT for angioplasty guidance. The company was established in India in 1910 and employs over 12,000 people in the country.

Differentiator

Problem solved

Functional benefit

Products and services

• FreeStyle Libre 2 Plus Sensor-based continuous glucose monitoring (CGM) system that provides real-time blood glucose trends through day and night, with continuous glucose readings every minute and optional alarms for people with diabetes (Type 1, Type 2, and gestational).
• AVEIR VR Leadless Pacemaker System World's only leadless pacemaker with unique mapping capability to assess correct positioning prior to placement. Features projected battery longevity of over 20 years and is designed to be retrieved when therapy needs evolve. Used by cardiology departments at hospitals such as Max Superspeciality Hospital and Apollo Hospitals Delhi for treatment of cardiac arrhythmias.
• AVEIR DR Dual Chamber Leadless Pacemaker System World's first dual chamber leadless pacemaker system with Beat to Beat Synchrony for treatment of patients with abnormal heart rhythms, eliminating the need for transvenous leads.
• Insertable Cardiac Monitor (ICM) Smartphone-compatible insertable cardiac monitor for detecting arrhythmias, no larger than two paper clips, that transmits data via Bluetooth to a dedicated mobile app. Used by electrophysiologists at Medanta Hospital, Fortis-Escorts Heart Institute, and Max Hospital Saket New Delhi for diagnosing infrequent cardiac arrhythmias including atrial fibrillation.
• MitraClip Transcatheter Clip Delivery System Minimally invasive heart valve repair device that clips portions of leaflets together to reduce backflow of blood in mitral regurgitation, delivered via catheter through a vein in the leg without open-heart surgery. Has helped treat more than 100,000 people worldwide and received the 2020 Prix Galien USA Award for Best Medical Technology.
• TactiFlex Sensor Enabled Ablation Catheter Sensor-enabled ablation catheter for treatment of abnormal heart rhythms through cardiac ablation procedures, introduced in India in May 2025.
• Navitor Vision Heart Valve Technology Next-generation heart valve technology designed to treat aortic stenosis, introduced in India in January 2025.
• 14-Valent Pneumococcal Conjugate Vaccine (PCV-14) Pneumococcal conjugate vaccine offering broadest protection for children against pneumococcal bacterial infections, targeting pediatric healthcare programs in India.
• Lab-based Blood Test for Concussion Evaluation Laboratory-based blood test to help evaluate concussion, made available in India in June 2025.
• Pea-sized PDA Closure Device Minimally invasive pea-sized closure device specifically designed for premature babies and newborns with Patent Ductus Arteriosus (PDA), a life-threatening opening between blood vessels in the heart, for infants weighing as little as 700 grams.
• Left Ventricular Assist Device (LVAD) with Full MagLev Flow Technology Left ventricular assist device for heart failure patients using full magnetic levitation technology to improve blood flow and reduce trauma to blood passing through the system.
• OCT (Optical Coherence Tomography) Intravascular Imaging Intravascular imaging technology used during angioplasty procedures to provide detailed images of blood vessels and help ensure precise stent placement.
• a:care Digital Health Platform Digital health platform and initiative focused on medication adherence. Combines digital solutions with behavioral science to help people stay on treatment plans for non-communicable diseases. Includes the a:care Congress educational initiative endorsed by 60+ national and international medical societies.
• Oral Anti-Diabetic Medicines (Novo Nordisk Partnership - semaglutide/Ozempic Extensior launch) Branded diabetes therapy offered through Abbott's distribution partnership with Novo Nordisk India, broadening access to semaglutide (Ozempic) for advanced diabetes management alongside Abbott's nutrition and continuous glucose monitoring portfolio.
• Oral Anti-Diabetic Medicines (MSD Partnership) Distribution arrangement with MSD for innovative oral anti-diabetic medicines in India, leveraging Abbott's distribution network to expand access for Indian patients with diabetes.

Quantifiable outcome

• MitraClip has helped treat more than 100,000 people worldwide with mitral regurgitation
• +6 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Six partnerships are on record, tiered core and minor.

• MSD (Merck)coreStrategic or Co-development Partner · 18 June 2025Abbott and MSD announced strategic partnership to distribute innovative oral anti-diabetic medicines in India. This partnership expands access to diabetes medications for Indian patients through Abbott's extensive distribution network.
• Association of Physicians of India (API)coreStrategic or Co-development Partner · 24 October 2024Abbott and API collaborated to improve medication adherence for better NCD management at Abbott's a:care Congress. This is one of the largest global educational initiatives on medication adherence, endorsed by more than 60 national and international medical societies.
• IQVIAminorStrategic or Co-development Partner · 4 July 2024Abbott commissioned an IQVIA survey among 1,250 people in India to better understand struggles experienced by people living with vertigo. Survey conducted across Mumbai, Delhi, Chennai, Bangalore, and Kolkata.
• Ayushmann KhurranaminorGTM or Marketing Partner · 4 July 2024Bollywood actor and UNICEF India Ambassador Ayushmann Khurrana partnered with Abbott for the 'Chakkar Ko Check Kar' campaign to raise awareness about vertigo. He shared his personal experience with vertigo diagnosed in 2016.
• Novo Nordisk IndiacoreStrategic or Co-development PartnerAbbott partnered with Novo Nordisk India to launch Extensior broadening access to semaglutide (Ozempic) for advanced diabetes management as a step forward towards holistic diabetes management along with nutrition and monitoring.
• Abbott Pandemic Defense Coalition PartnerscoreStrategic or Co-development PartnerAbbott Pandemic Defense Coalition is a network of more than 20 scientific and public health organizations around the globe focused on identifying, tracking and responding to known and emerging disease outbreaks. Partners include Centers for Research in Emerging Infectious Diseases (CREID) Network, Global Virus Network (GVN), and Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET).

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Dexcom: Primary CGM competitor to FreeStyle Libre globally and in India. Targets the same diabetes patient and endocrinologist segments with continuous glucose monitoring hardware and digital tools.
• Medtronic (India): Direct competitor in cardiac rhythm management, structural heart, and cardiac ablation in India. Overlaps with Abbott in pacemakers (including leadless platforms), ablation catheters, and heart failure devices, addressing the same hospital cardiology customer base.
• Cipla: Indian pharma major competing with Abbott's branded generics in respiratory, cardiovascular, and chronic therapy areas, addressing overlapping physician and pharmacy channels across India.
• Edwards Lifesciences: Direct peer in transcatheter structural heart therapies (PASCAL system competing with MitraClip) and surgical heart valves, with growing India presence in aortic stenosis treatment alongside Abbott's Navitor Vision platform.
• Dr. Reddy's Laboratories: Indian pharma peer with overlapping branded generics portfolio across cardiovascular, diabetes, and gastrointestinal therapy areas. Competes for the same physician channel and patient adherence programs in India.
• Boston Scientific (India): Competes with Abbott in cardiac rhythm management, structural heart (including transcatheter mitral repair), and peripheral vascular interventions across Indian hospital channels, sharing similar electrophysiology and structural heart call points.
• Siemens Healthineers (India): Direct peer in the diagnostics and laboratory equipment segment in India, addressing the same hospital and reference-lab customer base as Abbott's diagnostics business.
• Roche Diagnostics (India): Competing diagnostic platform across clinical chemistry, immunoassays, and molecular diagnostics in India, overlapping with Abbott's central lab and point-of-care diagnostics offerings.

Broad incumbents

• Johnson & Johnson MedTech (India): Broad incumbent across cardiovascular, surgical, and orthopedics portfolios in India. Overlaps with Abbott in hospital-channel cardiac and surgical device categories while operating as a much wider medical device conglomerate.
• GE HealthCare (India): Broad incumbent in diagnostics, imaging, and patient monitoring across Indian hospitals. Overlaps with Abbott in diagnostics while also competing in adjacent imaging and monitoring categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/AbbottNews
• YouTubeyoutube.com/c/abbott
• Facebookfacebook.com/AbbottIndia
• LinkedInlinkedin.com/company/mycompany
• Instagraminstagram.com/abbottglobal

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abbott (Abbott India)